Safety and efficacy of two doses of belzutifan in patients (pts) with advanced RCC: Results of the randomized phase II LITESPARK-013 study

被引：5

作者：

Agarwal, N. ^{[1
]}

Brugarolas, J. ^{[2
]}

Ghatalia, P. ^{[3
]}

George, S. ^{[4
]}

Haanen, J. B. A. G. ^{[5
]}

Gurney, H. P. ^{[6
]}

Ravilla, R. ^{[7
]}

Van der Veldt, A. A. M. ^{[8
]}

Beuselinck, B. ^{[9
]}

Pokataev, I. ^{[10
]}

Suelmann, B. B. ^{[11
]}

Tuthill, M. ^{[12
]}

Vaena, D. ^{[13
]}

Zagouri, F. ^{[14
]}

Wu, J. ^{[15
]}

Liu, Y. ^{[15
]}

Perini, R. ^{[15
]}

Merchan, J. R. ^{[16
]}

Atkins, M. B. ^{[17
]}

机构：

[1] Huntsman Canc Inst, Oncol Internal Med Dept, Salt Lake City, UT USA

[2] Univ Texas Southwestern Med Ctr, Internal Med Hematol Oncol, Dallas, TX USA

[3] Fox Chase Canc Ctr, Hematol Oncol, Philadelphia, PA USA

[4] Roswell Pk Canc Inst, Oncol, Buffalo, NY USA

[5] Netherlands Canc Inst, Oncol, Amsterdam, Netherlands

[6] Macquarie Univ, Oncol, Sydney, NSW, Australia

[7] Albany Canc Ctr, Oncol, New York Oncol Hematol, Albany, NY USA

[8] Erasmus MC, Oncol, Rotterdam, Netherlands

[9] UZ Leuven, Oncol, Leuven, Belgium

[10] City Clin Oncol Hosp 1, Oncol, Moscow, Russia

[11] Univ Med Ctr Utrecht, Med Oncol, Utrecht, Netherlands

[12] Oxford Univ Hosp NHS Fdn Trust, Oncol & Hematol, London, England

[13] West Canc Ctr & Res Inst, Oncol, Germantown, TN USA

[14] Alexandra Reg Gen Hosp, Oncol, Athens, Greece

[15] Merck & Co Inc, Oncol, Rahway, NJ USA

[16] Univ Miami Hosp & Clin, Oncol, Sylvester Canc Ctr, Canc Res Serv, Miami, FL USA

[17] Georgetown Univ, Oncol, Med Ctr, Washington, DC USA

来源：

ANNALS OF ONCOLOGY | 2023年 / 34卷

关键词：

D O I：

10.1016/j.annonc.2023.09.1111

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

1881O

引用

页码：S1011 / S1011

页数：1

共 50 条

[21] Efficacy, safety and predictive biomarker results from a randomized phase II study comparing atezolizumab vs docetaxel in patients with advanced NSCLC (POPLAR)
Schulz, C.
Spira, A., I
Park, K.
Mazieres, J.
Vansteenkiste, J.
Ballinger, M.
Waterkamp, D.
Fehrenbacher, L.
ONCOLOGY RESEARCH AND TREATMENT, 2016, 39 : 104 - 104
[22] Belzutifan monotherapy in Chinese patients (pts) with von Hippel-Lindau (VHL) disease-associated tumors: Results of LITESPARK-015 study.
Qiu, Jianhui
Zhou, Jingcheng
Cai, Lin
Kong, Wen
Xue, Wei
Zhang, Jin
Dong, Pei
Liu, Jie
Li, Wanyu
Li, Nan
Naik, Girish S.
Gong, Kan
JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (5_SUPPL) : 534 - 534
[23] Results of the randomized, placebo (PL)-controlled phase II study evaluating the efficacy and safety of regorafenib (REGO) in patients (pts) with relapsed advanced or metastatic chordoma, on behalf of the French Sarcoma Group (FSG) and Unicancer
Duffaud, F.
Chabaud, S.
Chevreau, C. M.
Italiano, A.
Perrin, C.
Isambert, N.
Piperno-Neumann, S.
Saada-Bouzid, E.
Bertucci, F.
Cupissol, D.
Kalbacher, E.
Narciso, B.
Schiffler, C.
Carvalho, N. de Sousa
Monard, L.
Bouvier, C.
Vidal, V.
Blay, J-Y.
Mir, O.
ANNALS OF ONCOLOGY, 2021, 32 : S1335 - S1335
[24] Safety and efficacy of sorafenib in patients with advanced renal cell carcinoma (RCC) with varying histologies: results from the phase 3, open access study of sorafenib in European patients with advanced RCC (EU-ARCCS)
Keilholz, U.
Gore, M.
Bracarda, I
Richel, N.
Staehler, M.
von der Maase, H.
Stierner, U.
Strauss, U. P.
Porta, C.
Bokemeyer, C.
ONKOLOGIE, 2010, 33 : 130 - 130
[25] Safety and efficacy of sorafenib in patients with advanced renal cell carcinoma (RCC) with varying histologies: results from the phase 3, open access study of sorafenib in European patients with advanced RCC (EU-ARCCS)
Bokemeyer, C.
Gore, M.
Bracarda, I.
Richel, N.
Staehler, D.
von der Maase, H.
Stierner, U.
Strauss, U. P.
Burock, K.
Porta, C.
EJC SUPPLEMENTS, 2009, 7 (02): : 433 - 433
[26] EFFICACY AND SAFETY OF SORAFENIB IN PTS WITH BRAIN AND BONE METASTASES: RESULTS FROM A LARGE OPEN-LABEL, NON-COMPARATIVE PHASE III STUDY OF SORAFENIB IN EUROPEAN PTS WITH ADVANCED RCC (EUARCCS)
Bokemeyer, C.
Porta, C.
Beck, J.
Negrier, S.
Richel, D. J.
Strauss, U. P.
Burrock, K.
Mersmann, S.
Szczylik, C.
Escudier, B.
ANNALS OF ONCOLOGY, 2008, 19 : 192 - 193
[27] Phase II study of futibatinib plus pembrolizumab in patients (pts) with advanced/metastatic urothelial carcinoma (mUC): Final analysis of efficacy and safety
Koshkin, V. S.
Barthelemy, P.
Gravis, G.
Goodman, O.
Duran, I.
Girones Sarrio, R.
Hwang, C.
Garcia-Donas, J.
Morales Barrera, R.
Zanetta, S.
Chisamore, M.
Liu, M.
Gil, M.
Tomlinson, G.
Elsayed, H.
Loriot, Y.
ANNALS OF ONCOLOGY, 2024, 35 : S1136 - S1137
[28] EFFECT OF DOSE ON EFFICACY AND SAFETY IN IPILIMUMAB-TREATED PATIENTS WITH ADVANCED MELANOMA - RESULTS FROM A PHASE II, RANDOMIZED, DOSE-RANGING STUDY
Lebbe, C.
Hoos, A.
Chin, K.
Li, J.
Neyns, B.
Linette, G.
Negrier, S.
Schadendorf, D.
Smylie, M.
Wolchok, J.
ANNALS OF ONCOLOGY, 2008, 19 : 239 - 240
[29] Final analysis of the phase III LITESPARK-005 study of belzutifan versus everolimus in participants (pts) with previously treated advanced clear cell renal cell carcinoma (ccRCC)
Rini, B. I.
Rodriguez, C. Suarez
Albiges, L.
Jalkanen, K.
Oria, G. A. De Velasco
Burotto, M.
Ghatalia, P.
Iacovelli, R.
Lam, E. T.
Verzoni, E.
Gumus, M.
Stadler, W.
Kollmannsberger, C. K.
Melichar, B.
Venugopal, B.
Lin, J.
Perini, R.
Vickery, D.
Choueiri, T. K.
Powles, T. B.
ANNALS OF ONCOLOGY, 2024, 35 : 1262 - 1263
[30] Randomized phase II study of two different doses of AVE0005 (VEGF Trap, aflibercept) in patients (pts) with metastatic renal cell carcinoma (RCC): An ECOG-ACRIN study [E4805].
Pili, Roberto
Manola, Judith
Carducci, Michael Anthony
Dutcher, Janice P.
Appleman, Leonard Joseph
Groteluschen, David L.
DiPaola, Robert S.
JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)

← 1 2 3 4 5 →